ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

Wet age-related macular degeneration (AMD) causes central vision loss, difficulty seeing in low light, and distorted vision. These changes can make daily tasks harder and may affect physical and ...

Q1 2026 Management view "The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

The last time I spoke about REGENXBIO (RGNX), it was with respect to a Seeking Alpha article entitled "Regenxbio: With Additional MPS II Data, Program Advancement Remains On Track". With respect to ...

Wet age-related macular degeneration (AMD) is caused by abnormal blood vessels damaging the macula in your eye, which can lead to central vision loss and difficulty seeing details or colors.

The FDA's complete response letter highlights insufficient efficacy evidence for bevacizumab-vikj in treating wet AMD, despite previous safety confirmations. NORSE EIGHT study failed its primary ...

・The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular previously said that positive results could support a New Drug Application ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...